Clinical Trial Search

Primary: Inhibition of the P2Y12 Receptor at 2 Hours After Loading Doses of Ticagrelor and Clopidogrel as Measured by P2Y12 Reaction Units (PRU) From VerifyNow™ — 98.4; 257.5 PRU…

Primary: Number of Spontaneous Bowel Movements in Patients With Multiple Sclerosis (MS)-Associated Constipation Per Day. — 3.4; 3.2 spontaneous bowel movements

Primary: Percentage of Participants Maintaining Average Hemoglobin Concentration Within the Target Range During the Efficacy Evaluable Period (EEP) — 53.9 percentage of…

Primary: Treatment Failure — 34; 50; 33 participants

Primary: Aberrant Behavior Checklist Hyperactivity Subscale — 19.3; 29.7 units on a scale

Primary: Difference in Ashworth Spasticity Scale Score Between Baseline and 12 Weeks — -1.55; -1.00 units on a scale

Primary: Change From Baseline (BL) in Total Awake Time Spent "Off" at Week 4 of Maintenance Period — -1.91; -2.04; -2.92; -2.34 Hours — p=0.814

Primary: Percentage of Participants Maintaining Average Hemoglobin (Hb) Concentration Within the Target Range — 77.1; 88.5; 90.9; 84.3 percentage of participants

Primary: Pocket Depth — 4.34; 4.81; 4.5 mm

Primary: Intraocular Pressure (IOP) in the Study Eye at 8 AM, 12 PM, and 4 PM — 16.4; 15.1; 16.0; 15.0 Millimeters of Mercury (mmHg)

Primary: Number of Participants Who Died and With Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, Grade 2-4 Related AEs, Grade 3-4 AEs, and…

Primary: Mycological Cure — 17; 28; 16; 13 Percentage of participants — p=<0.05

Primary: Asthma Control Test (ACT) — 2.95; 2.44 units on a scale

Primary: Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator — 0.20; 0.29 Proportion of participants

Primary: LNG Steady State at Baseline and Then Post-randomization — 3.82; 3.13; 3.01; 3.58 ng/mL